Tofacitinib Response in Ulcerative Colitis (TOUR): Early Response After Initiation of Tofacitinib Therapy in a Real-world Setting.

Millie D LongAnita AfzaliMonika FischerDavid HudesmanMaisa AbdallaRobert McCabeBenjamin L CohenRyan C UngaroWill HarlanJohn HansonGauree KonijetiSteven PolyakTimothy RitterBruce SalzbergJennifer SeminerioEmily EnglishXian ZhangPuza P SharmaHans H Herfarth

Published in: Inflammatory bowel diseases (2022)

In this prospective real-world study, tofacitinib resulted in a rapid and persistent improvement in UC disease activity PROs. The safety findings were consistent with the established safety profile of tofacitinib.

Keyphrases

rheumatoid arthritis
ulcerative colitis
disease activity
rheumatoid arthritis patients
systemic lupus erythematosus
ankylosing spondylitis
juvenile idiopathic arthritis
stem cells
mesenchymal stem cells
bone marrow
loop mediated isothermal amplification